Last reviewed · How we verify
A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to investigate the efficacy and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with a PD-1/CTLA-4 bispecific antibody (Cadonilimab) in combination with platinum-containing chemotherapy (Paclitaxel Polymeric Micelles for Injection combined with Cisplatin). Includes pathologic complete remission rates (pCR rates) after 2-4 cycles of Cadonilimab combination chemotherapy. The objective remission rate (ORR), major pathologic remission rate (MPR), R0 resection rate and 2-year overall survival (OS) and progression-free survival (OS) rates, and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with Cadonilimab combined with chemotherapy.
Details
| Lead sponsor | Sun Jing |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 30 |
| Start date | Sun Apr 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Oct 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Neoadjuvant Therapy
Interventions
- Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab
Countries
China